Download PDF
Drug Res (Stuttg) 2024; 74(02): 77-80
DOI: 10.1055/a-2234-1797
Original Article

Effects of SGLT2 Inhibitors and DPP-4 Inhibitors on Advanced Glycation End Products

Masataka Kusunoki
1   Department of Diabetes, Motor Function and Metabolism, Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya City, Aichi, Japan
,
Fumiya Hisano
2   Graduate School of Medicine, Department of Integrated Health Sciences, Nagoya University, Nagoya City, Aichi, Japan
,
Shin-ichi Matsuda
3   Department of Data Science, Faculty of Science and Technology, Nanzan University, Nagoya City, Aichi, Japan
,
Akiko Kusunoki
4   Akishima Clinic. Sakae, Naka-ku, Nagoya City, Japan
,
Tomokazu Abe
1   Department of Diabetes, Motor Function and Metabolism, Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya City, Aichi, Japan
,
Kazuhiko Tsutsumi
5   Okinaka Memorial Institute for Medical Research, Tokyo, Japan
,
Tetsuro Miyata
6   Office of Medical Education, School of Medicine, International University of Health and Welfare, Narita City, Chiba, Japan
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Clinical trials have revealed that sodium glucose cotransporter 2 (SGLT2) inhibitors suppress the onset of heart failure and cardiovascular death in diabetic patients. On the other hand, few reports have been published concerning such effects of dipeptidyl peptidase-4 (DPP-4) inhibitors. We undertook the present study to evaluate the effects of SGLT2 inhibitors and DPP-4 inhibitors on the advanced glycation end products (AGEs), well known as a risk factor for the development of cardiovascular disorders.

Type 2 diabetes mellitus were divided into two groups and treated with either SGLT2 inhibitors or DPP-4 inhibitors for 3 months. Before and after the 3-month treatment period with each drug, the AGEs and diabetes-related parameters were measured. Methylglyoxal-derived hydroimidazolone-1 (MG-H1) was measured as one of the AGEs.

In the SGLT2 inhibitor group, both the blood HbA1c and MG-H1 levels decreased significantly after the 3-month treatment period. In the DPP-4 inhibitor group, only the blood HbA1c level decreased significantly, with no significant change of the blood MG-H1 level.

SGLT2 inhibitor reduced both the blood levels of HbA1c and AGEs (MG-H1). Considering that the blood levels of AGEs are associated with the risk of heart failure and cardiovascular disorders, the results of the present study suggest that the effect of SGLT2 inhibitors in suppressing cardiovascular death might be mediated by the reduction in the blood levels of AGEs induced by this class of drugs. DPP-4 inhibitors showed no significant effects on the blood levels of AGEs.

Key words

SGLT2 inhibitor - DPP-4 inhibitor - advanced glycation end products - MG-H1 - type 2 diabetes mellitus


Publication History

Received: 18 October 2023

Accepted: 20 December 2023

Article published online:
29 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med 2013; 34: 183-196
    CrossrefPubMedGoogle Scholar
  • 2 Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794
    CrossrefPubMedGoogle Scholar
  • 3 DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obesity and Metabolism 2012; 14: 5-14
    CrossrefPubMedGoogle Scholar
  • 4 Seino Y, Sasaki T, Fukatsu A. et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, Phase 3 study. Current Medical Research & Opinion 2014; 30: 1245-1255
    CrossrefPubMedGoogle Scholar
  • 5 Wanner C, Inzucchi SE, Lachin JM. et al. EMPA-REG OUTCOME Investigators: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
    CrossrefPubMedGoogle Scholar
  • 6 Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med 2022; 386: 2042-2034
    CrossrefPubMedGoogle Scholar
  • 7 Uribarri J, Cai W, Ramdas M. et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role AGER 1, and SIRT 1. Diabetes Care 2011; 34: 1610-1616
    CrossrefPubMedGoogle Scholar
  • 8 Ueda S, Yamagishi S, Matsui T. et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012; 30: 249-254
    PubMedGoogle Scholar
  • 9 Kim YG, Hahn S, Oh TJ. et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708
    CrossrefPubMedGoogle Scholar
  • 10 Esposito K, Cozzolino D, Bellastella G. et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603
    CrossrefPubMedGoogle Scholar
  • 11 Yamanaka M, Matsumura T, Ohno R. et al. Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. J Clin Biochem Nutr 2016; 58: 135-140
    CrossrefPubMedGoogle Scholar
  • 12 Ueda S, Yamagishi S, Mataui T. et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012; 30: 249-254
    CrossrefPubMedGoogle Scholar
  • 13 Yamagishi S, Fujimori H, Yonekura H. et al. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biophy Res Commun 1999; 258: 353-357
    CrossrefPubMedGoogle Scholar
  • 14 Tomosugi N, Yamamoto S, Takeuchi M. et al. Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans. J Atheroscler Thromb 2017; 24: 530-538
    CrossrefPubMedGoogle Scholar
  • 15 Sharma C, Kaur A, Thind SS. et al. Advanced glycation End-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 2015; 52: 7561-7576
    CrossrefPubMedGoogle Scholar